Sphere Fluidics Trademarks Cyto-Mine


Sphere Fluidics has filed a Trademark for Cyto-Mine, its new single cell analysis instrument, in Europe. “We are also trademarking this novel, brand name in the US and will consider other regions shortly.” said Dr Frank F. Craig (CEO). “Sphere Fluidics believes that this technology will be breakthrough for biopharmaceutical discovery and development. To date, we have taken great care in developing our IP portfolio and will continue to do so to ensure protection of our valuable assets”.

Sphere Fluidica to exhibit at the RSC Emerging Technologies Conference


Sphere Fluidics will be exhibiting at the Royal Society of Chemistry Emerging Technologies Conference to be held in London (UK) on 25th June 2014. Dr Xin Li (Group Leader, Chemistry) and Dr David Holmes (Principal Engineer) will be present to discuss Sphere Fluidics’ single cell analysis platforms. “Our core technology was based on inventions made in the Chemistry Department at the University of Cambridge, so visitors can see how companies develop novel chemistry into leading products and technology platforms.” said Dr Li.”Visitors can also get information on our new Cyto-Mine single cell analysis platform which we have now started to develop.” said Dr Holmes. Conference information can be found here.

Sphere Fluidics to Globally Launch New Cyto-Mine Platform at BIO2014


Sphere Fluidics will be launching its vision for development of its’ new Cyto-Mine platform at BIO2014 (being held in San Diego during June 23rd-26th 2014). Dr Frank F. Craig (CEO), Dr Marian Rehak (Director of R&D) and Dr Rob Marchmont (Commercial Director) will be attending. “This new system will perform novel single cell and cell:cell or cell:biomolecule assays on millions of cells and also ensure enhanced monoclonality of isolated “hits.” said Dr Rehak. “This new platform will accelerate biopharmaceutical discovery and development. We are also now starting to collaborate with leading biopharmaceutical companies to help shape the features of this exciting new platform.” said Dr Marchmont. “We will also be exhibiting at Booth #3317 in the UK Pavilion and are meeting a number of top firms for biopartnering discussions, so this will be an excellent meeting for Sphere Fluidics.” said Dr Craig. More information can be found here.